Conference Coverage

L-Selectin Level May Help Stratify Patients at Risk of PML


 

References

Treatment decisions are influenced by unchangeable factors, such as previous immune suppression, and dynamic biomarkers, such as treatment duration and JCV antibody seropositivity. “Then you have two additional parameters that might be helpful for individual treatment decisions: JCV index and L-selectin,” concluded Dr. Wiendl.

Erik Greb

Pages

Recommended Reading

Alemtuzumab’s Benefits May Be Sustained for Three Years in Patients With MS
ICYMI Multiple Sclerosis
Can Lesion Volume and Brain Atrophy Predict Outcomes in Early MS?
ICYMI Multiple Sclerosis
Automating and Improving the EDSS—Validation of the eEDSS
ICYMI Multiple Sclerosis
Alasdair Coles, MD
ICYMI Multiple Sclerosis
Letizia Leocani, MD, PhD
ICYMI Multiple Sclerosis
Age and DMT Exposure May Predict Conversion From Clinically Isolated Syndrome to MS
ICYMI Multiple Sclerosis
Sodium Intake Is Linked to Increased Disease Activity in MS
ICYMI Multiple Sclerosis
Computerized Cognitive Test May Be a Valid Assessment for Patients With MS
ICYMI Multiple Sclerosis
More Than 45 Novel MS Susceptibility Variants Are Identified
ICYMI Multiple Sclerosis
Does MS Begin With Radiologically Isolated Syndrome?
ICYMI Multiple Sclerosis